NOX for locally advanced unresectable (LAPC) and borderline resectable
(BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 2015;22:1153–9.
81. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine
vs observation in patients undergoing curative-intent resection of pancreatic
cancer: a randomized controlled trial. JAMA 2007;297:267–77.
82. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of
action, and self-potentiation. Semin Oncol 1995; 22( 4 Suppl 11): 3–10.
83. Sahora K, Kuehrer I, Eisenhut A, et al. NeoGemOx: Gemcitabine and
oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized
pancreatic cancer. Surgery 2011;149( 3):311–20.
84. Lee JL, Kim SC, Kim JH, et al. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for
borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. Surgery 2012;152:851–62.
85. Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin
therapy followed by a twice-weekly infusion of gemcitabine and concurrent
external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013;119:277–84.
86. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensiti-zation. Semin Oncol 1997; 24( 2 Suppl 7):S7–24-S27–28.
87. Kang CM, Chung YE, Park JY, et al. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative
resection in borderline resectable pancreatic cancer. J Gastrointest Surg
88. Chuong MD, Hayman TJ, Patel MR, et al. Comparison of 1-, 2-, and 3-dimen-
sional tumor response assessment after neoadjuvant GTX-RT in borderline-resectable pancreatic cancer. Gastrointest Cancer Res 2011;4:128–34.
89. Loehrer AP, Kinnier CV, Ferrone CR. Treatment of locally advanced pancreatic ductal adenocarcinoma. Adv Surg 2016;50:115–28.
90. Katz MH, Wang H, Balachandran A, et al. Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer. J
Gastrointest Surg 2012;16:68–78.
91. Franke AJ, Rosati LM, Pawlik TM, et al. The role of radiation therapy in
pancreatic ductal adenocarcinoma in the neoadjuvant and adjuvant settings.
Semin Oncol 2015;42:144–62.
92. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins
and treatment on survival in patients with pancreatic cancer: meta-analysis of
randomized controlled trials. Arch Surg 2008;143:75–83.
93. Paniccia A, Hosokawa P, Henderson W, et al. Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma. JAMA Surg 2015;150:701–10.
94. Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after
chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of
perioperative outcome and survival. Ann Surg Oncol 2006;13:1201–8.
95. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and
IMRT-based chemoradiation for borderline resectable pancreatic cancer. J
Surg Oncol 2011;104:155–161.
96. Landry J, Catalano PJ, Staley C, et al. Randomized phase II study of gemcitabine
plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by
radiotherapy and 5-fluorouracil for patients with locally advanced, potentially
resectable pancreatic adenocarcinoma. J Surg Oncol 2010;101:587–92.
97. Lamb R, Ozsvari B, Lisanti CL, et al. Antibiotics that target mitochondria
effectively eradicate cancer stem cells, across multiple tumor types: treating
cancer like an infectious disease. Oncotarget 2015;6:4569–84.
98. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol
99. White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients
with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol
100. Martin RC 2nd. Management of locally advanced pancreatic cancer. Surg
Clin North Am 2016;96:1371–89.
101. Higuera O, Ghanem I, Nasimi R, et al. Management of pancreatic cancer in
the elderly. World J Gastroenterol 2016;22:764–75.
102. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older
adults. Br J Cancer 2008;98:517–22.
103. Spadi R, Brusa F, Ponzetti A, et al. Current therapeutic strategies for
advanced pancreatic cancer: A review for clinicians. World J Clin Oncol
104. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P, Group EGW. Pancreatic
adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis,
treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii33–40.
105. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic
review. J Clin Oncol 2009;27:2269–77.
106. Suker M, Beumer BR, Sadot E, et al. FOLFIRINOX for locally advanced
pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet
107. Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and
metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013;30:361.
108. Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or
capecitabine-based chemoradiotherapy for locally advanced pancreatic
cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol
109. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer
with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691–1703.
110. Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness.
J Clin Oncol 2003;21:3409–14.
111. Sultana A, Tudur Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of
secondary end points analyses. Br J Cancer 2008;99: 6–13.
112. Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy
vs chemotherapy on survival in patients with locally advanced pancreatic
cancer controlled after 4 months of gemcitabine with or without erlotinib:
the LAP07 randomized clinical trial. JAMA 2016;315:1844–53.
113. Huguet F, Andre T, Hammel P, et al. Impact of chemoradiotherapy after
disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326–31.
114. Dholakia AS, Hacker-Prietz A, Wild AT, et al. Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend
on improved radiographic appearance of tumor-vessel relationships. J Radiat
115. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol 2013;24:2484–92.
116. Morganti AG, Trodella L, Valentini V, et al. Pain relief with short-term
irradiation in locally advanced carcinoma of the pancreas. J Palliat Care
117. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic
cancer pain in adults. Cochrane Database Syst Rev 2011( 3):CD007519.
118. Pezzilli R, Andriulli A, Bassi C, et al. Exocrine pancreatic insufficiency in
adults: a shared position statement of the Italian Association for the Study of
the Pancreas. World J Gastroenterol 2013;19:7930–46.
119. Dominguez-Munoz JE. Pancreatic exocrine insufficiency: diagnosis and
treatment. J Gastroenterol Hepatol 2011; 26 Suppl 2: 12–16.
120. Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric
coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998;42:92–6.
121. Wright AA, Keating NL, Balboni TA, et al. Place of death: correlations with
quality of life of patients with cancer and predictors of bereaved caregivers’
mental health. J Clin Oncol 2010;28:4457–64.
122. Jang RW, Krzyzanowska MK, Zimmermann C, et al. Palliative care and the
aggressiveness of end-of-life care in patients with advanced pancreatic cancer.
J Natl Cancer Inst 2015;107( 3). pii: dju424.